Literature DB >> 11918687

Fas ligand and the fate of antitumour cytotoxic T lymphocytes.

Joe O'Connell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11918687      PMCID： PMC1782665          DOI： 10.1046/j.1365-2567.2002.01379.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  18 in total

1.  Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.

Authors:  H Nagashima; M Mori; N Sadanaga; K Mashino; Y Yoshikawa; K Sugimachi
Journal:  Int J Oncol       Date:  2001-06       Impact factor: 5.650

2.  Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.

Authors:  K Okada; K Komuta; S Hashimoto; S Matsuzaki; T Kanematsu; T Koji
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

3.  Immune privilege or inflammation? Insights into the Fas ligand enigma.

Authors:  J O'Connell; A Houston; M W Bennett; G C O'Sullivan; F Shanahan
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

4.  Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.

Authors:  Jie-Hui Li; Dalia Rosen; Paul Sondel; Gideon Berke
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

5.  Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids.

Authors:  A Lepple-Wienhues; C Belka; T Laun; A Jekle; B Walter; U Wieland; M Welz; L Heil; J Kun; G Busch; M Weller; M Bamberg; E Gulbins; F Lang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

6.  Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?

Authors:  X Ni; P Hazarika; C Zhang; R Talpur; M Duvic
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

7.  Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.

Authors:  M Shibakita; M Tachibana; D K Dhar; T Kotoh; S Kinugasa; H Kubota; R Masunaga; N Nagasue
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

8.  Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack.

Authors:  C Zietz; U Rumpler; M Stürzl; U Löhrs
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

9.  Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival.

Authors:  A M Hohlbaum; S Moe; A Marshak-Rothstein
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

10.  Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms.

Authors:  S Munakata; T Enomoto; M Tsujimoto; Y Otsuki; H Miwa; H Kanno; K Aozasa
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640
View more
  7 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

3.  STAT5B: A Differential Regulator of the Life and Death of CD4+ Effector Memory T Cells.

Authors:  Sonia S Majri; Jill M Fritz; Alejandro V Villarino; Lixin Zheng; Chrysi Kanellopoulou; Benjamin Chaigne-Delalande; Juha Grönholm; Julie E Niemela; Behdad Afzali; Matthew Biancalana; Stefania Pittaluga; Ashleigh Sun; José L Cohen; Steven M Holland; John J O'Shea; Gulbu Uzel; Michael J Lenardo
Journal:  J Immunol       Date:  2017-11-29       Impact factor: 5.422

Review 4.  The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.

Authors:  Frédéric Rieux-Laucat; Aude Magérus-Chatinet; Bénédicte Neven
Journal:  J Clin Immunol       Date:  2018-06-17       Impact factor: 8.317

5.  FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors.

Authors:  Ivy A Ho; Wai H Ng; Paula Y Lam
Journal:  Mol Cancer       Date:  2010-10-13       Impact factor: 27.401

Review 6.  Distributed Adaptive Search in T Cells: Lessons From Ants.

Authors:  Melanie E Moses; Judy L Cannon; Deborah M Gordon; Stephanie Forrest
Journal:  Front Immunol       Date:  2019-06-13       Impact factor: 7.561

7.  Understanding the Effects of Age and T-Cell Differentiation on COVID-19 Severity: Implicating a Fas/FasL-mediated Feed-Forward Controller of T-Cell Differentiation.

Authors:  Anthony J Leonardi; Christos P Argyropoulos; Adam Hamdy; Rui B Proenca
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.